The EU-GMP Blind Spot That's Locking APAC Cannabis Out of Europe

For years, the path from an Asia-Pacific grow room to a European pharmacy shelf was treated as a logistical challenge — a matter of certificates, shipping lanes, and finding the right import partner. A ruling issued in June 2026 by a German state health authority has made clear that it is, above all, a regulatory one. And many producers are still planning for the wrong audience.

The Person Who Actually Decides

Every batch of cannabis that enters the European Union's pharmaceutical supply chain must be released by a Qualified Person (QP) — a named individual at a licensed importing manufacturer who bears personal legal responsibility for that decision. Writing in Business of Cannabis, Dr Nickel Dittrich, Managing Director of consultancy GMPion, frames the QP as the real gatekeeper of market access: produce for the certificate on your wall rather than for what that person needs before they sign, and you are producing for the wrong audience.

It is a deceptively simple point with significant consequences. The QP is not reviewing export documents from Bangkok or Sydney. They are reviewing whether every step in the production chain — from field to finished flower — meets the standards they can legally vouch for. When a step falls outside a GMP-certified environment, the QP's exposure grows, and the likelihood of a release signature shrinks.

What Hesse Changed in June 2026

The Hessian State Office for Health and Care (HLfGP) issued guidance on 8 June 2026 that tightened the interpretation of a long-standing provision in the EU-GMP guidelines. Annex 7 of those guidelines permits initial cutting and drying in the field under Good Agricultural and Collection Practice (GACP), where a marketing authorisation justifies it. Further processing falls under GMP.

HLfGP inspectors found that GMP steps were being carried out at non-GMP-certified sites — a practice that had become common across supply chains linking Asian producers to German importers. The regulator's guidance clarified four requirements, two of which take immediate effect: import applications must now include a site-by-site, step-by-step map of which activities are conducted under GACP and which under GMP; and importers holding existing authorisations are expected to review their processes and submit a gap analysis.

When the specialist publication Krautinvest.de surveyed other German state regulators in July 2026, most said they shared or reached the same conclusion as Hesse. Saxony and Saxony-Anhalt indicated a preference for case-by-case decisions; Bavaria did not respond.

The Practical Consequence: Drying Is Now the Line

The ruling does not abolish the route by which raw cannabis enters Germany as a herbal starting material rather than a finished medicinal product. What it does is narrow what still qualifies as raw material. If drying and trimming are GMP steps, then flower that has been dried and trimmed at origin is already a GMP product. To enter Germany as cannabis flower under that classification, it requires a section 72a certificate — which in practice means a German regulatory inspection of the originating site.

Thailand illustrates the gap clearly. The Department of Thai Traditional and Alternative Medicine (DTAM) listed 217 certified GACP growing sources in its register as of February 2026, and Thailand's head of medical cannabis exports, Dr Peeracha Kuekasemkit, reported cannabis and hemp exports of 2.5 billion baht to 31 countries. Germany, the Czech Republic, Switzerland, and Portugal are among European buyers. Yet no Thai cannabis site appears in EudraGMDP, the EU's database of GMP certificates — a structural absence that reflects the absence of a mutual recognition agreement between Thailand and the EU.

Australia is in a different position. Under its mutual recognition agreement with the EU, confirmed by the European Medicines Agency as covering herbal medicines classified as medicinal products, EU authorities can rely on Australian GMP inspections and in some circumstances waive batch testing on import. That does not resolve every question — including whether HLfGP's guidance applies in full to products certified under such an agreement — but it removes the inspection hurdle that Thai producers still face.

What This Means for European Importers and Mediterranean Markets

The European medical cannabis import market includes several Mediterranean countries — Portugal, Greece, Italy, and Malta all operate some form of medical cannabis framework, though the scale and route-to-patient infrastructure differs significantly across them. Malta's medical cannabis programme operates separately from the adult-use framework established under Malta's 2021 cannabis reform, and medical cannabis products imported into Malta must meet EU pharmaceutical standards in the same way they would anywhere else in the bloc.

For European importers sourcing from APAC producers, the immediate practical tasks are documentation and process mapping. Any supply chain that previously relied on drying and trimming under GACP at origin — and completing further processing under GMP in Europe — now needs to be reviewed against the HLfGP framework. If the same interpretation is adopted across more German states, and potentially other EU regulators, the consequences for established supply arrangements could be significant.

For APAC producers, the calculus is more fundamental. Those who want to maintain flower export routes to Germany should begin planning for GMP-grade drying and trimming infrastructure at the farm level, and anticipate that a European inspector may need to visit and verify it.

The Takeaway

The HLfGP ruling has not closed European markets to Asia-Pacific cannabis — but it has moved the compliance bar to the farm gate. Producers who invest in bringing their on-site processing up to GMP standard, and who make the release decision straightforward for the Qualified Person at the other end of the chain, will retain access. Those who treat the ruling as paperwork risk finding their batches stalled at the point where a single person has to sign their name to the release.

Sources:

Dr Nickel Dittrich, GMPion, via Business of Cannabis — “What APAC Producers Get Wrong About EU-GMP”: https://businessofcannabis.com/what-apac-producers-get-wrong-about-eu-gmp/

Featured image: Photo by Jess Loiterton on Pexels